Reliance Life Sciences
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Reliance Life Sciences
US Drug Shortages Aid Aurobindo’s Q4 Growth, Decentralized Trials On For Xolair Biosimilar
Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair, as predicted by Scrip earlier. Use of decentralized mode for its Phase III trials is a notable aspect
Coronavirus Update: Pfizer/BioNTech Vaccine Shows Antibody Response In Young Kids
The companies announced data from their Phase II/III study in children aged 5-11 and intend to take them to regulators to expand Comirnaty's authorization; also, an expert panel advising India's drug regulator endorsed plans for a Phase III trial of a single-dose Russian vaccine, Sputnik Light, and vaccines from other Indian firms progress.
Watch This Space: Reliance Advances Protein-Based COVID-19 Vaccine
Reliance Life Sciences, part of India’s largest private sector enterprise with a growing engagement in healthcare, is progressing an early-stage COVID-19 vaccine. A top executive underscores the potential to manufacture at scale and provide the protein-based candidate at a competitive price.
2021 Deal Action In India: Watch Private Equity And E-Pharmacy
Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.